Three STI Professors win ERC Consolidator Grants

Left to right: Sophia Haussener, Li Tang, and Maryam Kamgarpour. 2025 EPFL CC BY SA
EPFL School of Engineering professors Sophia Haussener, Maryam Kamgarpour, and Li Tang have been awarded prestigious European Research Council (ERC) Consolidator Grants.
The ERC announced the winners in a press release on Tuesday. Sophia Haussener, head of the Laboratory of Renewable Energy Science and Engineering (LRESE) received a grant for her project DREAM (Democratization of Solar Renewable Energy Adapted for the New Millennium); Maryam Kamgarpour, head of the Systems Control and Multiagent Optimization Research Lab (SYCAMORE), was selected for the project CONCISE (Control for Safety-Constrained Interactive Systems); and Li Tang of the Laboratory of Biomaterials for Immunoengineering was selected for the project MechanoCAR (Mechanical sensing and reprogramming of CAR-engineered lymphocytes for next-generation ACT cancer immunotherapy). Olga Fink and Charlotte Grossiord of the School of Architecture, Civil and Environmental Engineering also received grants.
The five EPFL scientists were among 349 mid-career researchers selected to receive Consolidator grants by the ERC, which awarded a total of €728 million in funding. The activity of the ERC is to provide attractive, long-term funding to support excellent investigators and their research teams to pursue ground- breaking, high-gain/high-risk research. ERC Consolidator grants of up to 2 million euros encourage investigator-driven frontier research in Europe through competitive funding across all fields, on the basis of scientific excellence. They are awarded over a period of five years to researchers of any nationality and age, with at least seven years of experience after PhD, and a scientific track record showing great promise. The funding mostly covers the employment of researchers and other staff to consolidate the grantees' teams.
Control for Safety-Constrained Interactive Systems (CONCISE) - Maryam Kamgarpour, SYCAMORE: This research program proposes a framework for ensuring safety and performance for multiagent stochastic dynamic games. Dynamic game theory provides a powerful foundation for addressing interactive decision-making problems. Recent advances in artificial intelligence have led to the development of scalable algorithms for such decision-making challenges, but such algorithms lack provable performance guarantees when applied to real-world systems. CONCISE will address this gap by developing a theoretical framework guided by real-world challenges. It will notably integrate recent breakthroughs in the fundamental fields of stochastic control, game theory and learning theory. The program will verify the developed algorithms on real-world problems in transportation, power systems, and robotics. Anticipated outcomes include foundational advances in multiagent stochastic control systems, and provable algorithms for their safety and predictability. These advances will help build trust in applying modern control and artificial intelligence tools to safety-critical engineering systems in our society.
Mechanical sensing and reprogramming of CAR-engineered lymphocytes for next-generation ACT cancer immunotherapy (MechanoCAR) - Li Tang, Laboratory of Biomaterials for Immunoengineering: Adoptive cell transfer (ACT) with cytotoxic lymphocytes, including chimeric antigen receptor (CAR)-T cells, is a powerful immunotherapy already demonstrating success against certain blood cancers. However, its efficacy in treating solid tumors remains limited, with durable responses being rare. MechanoCAR explores a novel, under-explored approach: mechanical reprogramming of cytotoxic lymphocytes, including CAR-T and CAR natural killer (NK) cells. We hypothesize that enhancing the mechano-sensitivity of the lymphocytes could overcome some key limitations of ACT therapies, particularly against resistant tumors. First, we aim to uncover and characterize the mechano-sensing and mechano-transduction mechanisms of CARs. Next, we will develop and test innovative mechanical reprogramming strategies to enhance the cytotoxic potential of CAR-T/NK cells in advanced tumor models and explore the therapeutic potential using patient-derived organoids. If successful, this work will provide insights into mechano-immunology, offer a blueprint for next-generation ACT immunotherapies, and improve outcomes for patients with challenging cancers.